Biochemical markers of fibrosis in patients with chronic hepatitis C: A comparison with prothrombin time, platelet count, and age-platelet index

Digestive Diseases and Sciences

Volumn 48, Issue 1, 2003, Pages 146-153

  Myers, Robert P ^a   De Torres, Mercedes ^a   Imbert Bismut, Françoise ^a   Ratziu, Vlad ^a   Charlotte, Frédéric ^a   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Biopsy; Diagnosis; Fibrosis; Hepatitis C; Platelet; Prothrombin time

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; BIOCHEMICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; COMPARATIVE STUDY; FEMALE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; SAMPLING; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

ADULT; BIOLOGICAL MARKERS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; PLATELET COUNT; PROTHROMBIN TIME; ROC CURVE;

EID: 0037280482     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021702902681     Document Type: Article

References (34)

1. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med;345:41-52, 2001
2. Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, Samarasinghe D, Kench J, Kaba S, Crewe E, Liddle C: Which patients with hepatitis C develop liver complications? Hepatology 31:513-520, 2000
3. Perrillo RP: The role of liver biopsy in hepatitis C. Hepatology;26:57S-61S, 1997
4. EASL International Consensus Conference on Hepatitis C: Paris, February 26-27, 1999. Consensus statement. J Hepatol 31:3-8, 1999
5. Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 32:477-481, 2000
6. Froehlich F, Lamy O, Fried M, Gonvers JJ; Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci 38:1480-1484, 1993
7. McGill DB, Rakela J, Zinsmeister AR, Ott BJ: A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 99:1396-1400, 1990
8. Perrault J, McGill DB, Ott BJ, Taylor WF: Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 74:103-106, 1978
9. Friedman SL, Maher JJ, Bissell DM: Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology 32:1403-1408, 2000
10. Friedman SL: Evaluation of fibrosis and hepatitis C. Am J Med 107:27S-30S, 1999
11. Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH: Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 15:386-390, 2000
12. Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ: Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 5:187-192, 1998
13. Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ: Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 44:624-630, 1999
14. Poynard T, Bedossa P: Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 4:199-208, 1997
15. Poynard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, Chaput JC: A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 100:1397-1402, 1991
16. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357:1069-1075, 2001
17. Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289-293, 1996
18. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 26:2S-10S, 1997
19. Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839-843, 1983
20. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 34:730-739, 2001
21. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825-832, 1997
22. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, Matsumoto K, Nakamura T, Takahashi H, Okamoto E, Fujimoto J: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5:226-230, 1999
23. Guillen MI, Gomez-Lechon MJ, Nakamura T, Castell JV: The hepatocyte growth factor regulates the synthesis of acute-phase proteins in human hepatocytes: divergent effect on interleukin-6- stimulated genes. Hepatology 23:1345-1352, 1996
24. Bacq Y, Schillio Y, Brechot JF, De Muret A, Dubois F, Metman EH: Decrease of haptoglobin serum level in patients with chronic viral hepatitis C. Gastroenterol Clin Biol 17:364-369, 1993
25. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, zum Buschenfelde KH, Blessing M: TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 276:G1059-1068, 1999
26. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR: Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31:828-833, 2000
27. Tiggelman AM, Boers W, Moorman AF, de Boer PA, Van der Loos CM, Rotmans JP, Chamuleau RA: Localization of alpha 2-macroglobulin protein and messenger RNA in rat liver fibrosis: evidence for the synthesis of alpha 2-macroglobulin within Schistosoma mansoni egg granulomas. Hepatology 23: 1260-1267, 1996
28. Kawser CA, Iredale JP, Winwood PJ, Arthur MJ: Rat hepatic stellate cell expression of alpha2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci (Colch) 95:179-186, 1998
29. Albanis E, Friedman SL: Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 5:315-334, v-vi, 2001
30. Bedossa P, Poynard T, Abella A, Aubert A, Pignon JP, Naveau S, Leluc R, Lemaigre G, Martin ED, Chaput JC: Apolipoprotein AI is a serum and tissue marker of liver fibrosis in alcoholic patients. Alcohol Clin Exp Res 13:829-833, 1989
31. Paradis V, Mathurin P, Ratziu V, Poynard T, Bedossa P: Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix. Hepatology 23:1232-1238, 1996
32. Myers RP, Benhamou Y, Bochet M, Imbert-Bismut F, Thibault V, Ratziu V, Charlotte F, Katlama C, Poynard T: Serum biochemical markers of liver fibrosis in human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-coinfected patients. J Hepatol 36:A50, 2002 (abstract)
33. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F: Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. The GERMED cyt-04 group. J Viral Hepat 9:128-133, 2002
34. Adams L, Rossi E, DeBoer B, Speers D, Macquillan G, Garas G, Jeffrey G: Use of fibrotest to predict liver fibrosis in hepatitis C: A replacement for liver biopsy? Gastroenterology, 122:159A, 2002 (abstract)